Elon Musk has put himself in their crosshairs

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Daniel N. Swisher, Jr. net worth and biography

Daniel Swisher, Jr. Biography and Net Worth

Director of Corcept Therapeutics

Daniel N. Swisher, Jr. has served as a member of our Board since June 2015. He has been the President and Chief Operating Officer of Jazz Pharmaceuticals since January 2018. From 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, a clinical-stage biopharmaceutical company. From 2005 to 2017, he was also its President. He joined Sunesis in 2001 and had previously served as the company’s chief business officer and chief financial officer. Prior to that, Mr. Swisher held a range of senior management roles, including Senior Vice president of Sales and Marketing at ALZA Corporation, a pharmaceutical and medical systems company, from 1992 to 2001. Mr. Swisher has served as Chairman of the board of directors of Cerus Corporation, a publicly traded biopharmaceutical company, since 2013. Mr. Swisher received his B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.

What is Daniel N. Swisher, Jr.'s net worth?: The estimated net worth of Daniel N. Swisher, Jr. is at least $5.86 million as of May 9th, 2024. Swisher, Jr. owns 107,045 shares of Corcept Therapeutics stock worth more than $5,864,996 as of November 14th. This net worth approximation does not reflect any other assets that Swisher, Jr. may own. Learn More about Daniel N. Swisher, Jr.'s net worth.
How do I contact Daniel N. Swisher, Jr.?: The corporate mailing address for Swisher, Jr. and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Daniel N. Swisher, Jr.'s contact information.
Has Daniel N. Swisher, Jr. been buying or selling shares of Corcept Therapeutics?: During the last quarter, Daniel N. Swisher, Jr. has sold $131,736.00 of Corcept Therapeutics stock. Most recently, Daniel N. Swisher, Jr. sold 2,200 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.88, for a transaction totalling $131,736.00. Learn More on Daniel N. Swisher, Jr.'s trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 269,472 shares worth more than $7,991,445.07. The most recent insider tranaction occured on November, 11th when Director Daniel N. Swisher, Jr. sold 2,200 shares worth more than $131,736.00. Insiders at Corcept Therapeutics own 20.5% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 11/11/2024.

Daniel N. Swisher, Jr. Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/11/2024	Sell	2,200	$59.88	$131,736.00
8/1/2024	Sell	150	$38.50	$5,775.00
7/1/2024	Sell	2,200	$32.81	$72,182.00
6/3/2024	Sell	2,200	$30.21	$66,462.00
4/1/2024	Sell	2,200	$25.30	$55,660.00
3/1/2024	Sell	2,200	$23.59	$51,898.00
2/1/2024	Sell	2,200	$22.00	$48,400.00
1/2/2024	Sell	2,200	$22.11	$48,642.00
12/1/2023	Sell	2,200	$25.47	$56,034.00
11/1/2023	Sell	2,200	$27.96	$61,512.00
10/2/2023	Sell	2,200	$27.32	$60,104.00
9/5/2023	Sell	2,200	$32.90	$72,380.00
9/1/2023	Sell	1,550	$32.73	$50,731.50
8/7/2023	Sell	2,850	$30.14	$85,899.00
9/2/2021	Sell	7,500	$21.70	$162,750.00	7,500
6/2/2021	Sell	7,500	$21.48	$161,100.00	7,500
4/5/2021	Sell	7,500	$24.14	$181,050.00	7,500
1/19/2021	Sell	5,000	$28.74	$143,700.00	5,000
10/19/2020	Sell	5,000	$17.66	$88,300.00	5,000
7/17/2020	Sell	5,000	$16.48	$82,400.00	5,000
5/22/2020	Sell	5,000	$16.10	$80,500.00	5,000

Daniel N. Swisher, Jr. Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $54.79

$54.51

$57.50

50 Day Range

MA: $45.70

$34.10

$59.60

2 Week Range

Now: $54.79

$20.84

$61.66

Volume

824,910 shs

Average Volume

1,186,686 shs

Market Capitalization

$5.74 billion

P/E Ratio

43.48

Dividend Yield

N/A

Beta

0.45